N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
N/A N=571 What Matters Most: Choosing the Right Breast Cancer Surgery for You
Breast Cancer
Primary: Change in Decision Quality: Knowledge Subscale — 2.83; 2.95; 2.77; 2.82 score on a scale — p=0.045
N/A N=934 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
Breast Cancer
Primary: 5-year Disease-Free Survival — 84.4; 87.8 percentage of participants — p=0.004
N/A N=68 Seroma Formation After Modified Radical Mastectomy With Flap Fixation Technique in Breast Cancer Patients
Breast-cancer
Primary: Seroma Formation — 54.27; 59.56; 102.21; 117.94 ml — p=<0.005
Phase 4 N=60 PEMF and PEC Blocks in Mastectomy Reconstruction Patients
Breast Cancer Female
Primary: Score on Visual Analog Scale (VAS) - 1 Hour Post-intervention — 6.64; 6.67; 4.62; 6.93 score on a scale
Phase 2 N=67 Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
BRCA1 Mutation Carrier · BRCA2 Mutation Carrier · Ductal Breast Carcinoma In Situ
Primary: Mean Levels of Telapristone Acetate in Breast Tissue — 2.82; 103 ng/g
Phase 2 N=47 Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction
Breast Cancer
Primary: Quality of Recovery Score — 165; 169 score on a scale
Phase 2 N=270 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Breast Cancer
Primary: Local Recurrence — 3.1 percentage of participants
N/A N=198 One-stage Breast Reconstruction Using Dermal Matrix/Implant Versus Two-stage Expander/Implant Procedure
Breast Cancer
Primary: BreastQ Quality of Life and Satisfaction Questionnaire — 65.32; 67.07 score on a scale — p=0.05
N/A N=13 Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
N/A N=228 Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast
Intraductal Carcinoma and Lobular Carcinoma in Situ
Primary: Proportion of Women Who Benefited of Performing Upfront Sentinel Lymph Node (SLN) Biopsy Ductal Carcinoma in Situ — 51 Participants
N/A N=17 Immediate Postmastectomy Breast Reconstruction (Strattice Breast)
Breast Cancer
Primary: Histology Sample Evaluations Assessing Incorporation of StratticeTM Reconstructive Tissue Matrix — 0; 82.8; 17.2; 0 percentage of breasts
Phase 1 N=35 Single Dose Partial Breast Radiotherapy
Breast Cancer
Primary: Maximum Tolerated Dose — 21 Gray (Gy)
N/A N=20 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Breast Cancer · Ductal Carcinoma in Situ
Primary: Ipsilateral Recurrence Rate — 0 participants
N/A N=32 Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT
Breast Cancer
Primary: Success Rate — 65.4 percentage of participants
Phase 1 N=20 Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Breast Cancer
Primary: Maximum Tolerated Dose (MTD) — 10 milligrams
N/A N=30 Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer
Breast Cancer
Primary: Acute Radiation Effects (Less Than 90 Days Post Treatment) — 0 Participants
N/A N=26 Surgical Treatment of Post-surgical Mastectomy Pain Utilizing the Regenerative Peripheral Nerve Interface
Post-Mastectomy Chronic Pain Syndrome
Primary: Change in Pain Level — 6.9; 0.6; 4.4; 2.5 score on a scale
Phase 2 N=26 Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
N/A N=34 Comparison of Pre-op and Post-op Pectoralis Nerve Block
Breast Cancer · Postoperative Pain · Anesthesia
Primary: Pain Score Assessment Using a Visual Analog Scale-Immediately Post-surgery — 1.6; 2.3 units on a scale
Phase 2 N=756 Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Breast Cancer
Primary: False Negative Rate (FNR) for Sentinel Lymph Node (SLN) Surgery After Chemotherapy When at Least 2 SLNs Were Excised in Women Initially Presenting With Biopsy-proven cN1…
Phase 3 N=2,108 Regional Anesthesia and Breast Cancer Recurrence
Breast Neoplasms
Primary: Number of Participants Who Had Breast Cancer Recurrence After Breast Cancer Surgery — 111; 102 participants — p=0.84
N/A N=60 Single Versus Double Drains After Mastectomy
Breast Cancer · Mastectomy
Primary: Patient Comfort Scale — 3; 3 units on a scale — p=0.490
Phase 3 N=740 Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 64; 71; 70 percentage of participants
Phase 3 N=5,611 Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer
Breast Cancer
Primary: Morbidity - Number of Participants With Residual Shoulder Abduction Deficit — 276; 200 Participants
Phase 2 N=133 MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ
DCIS
Primary: Local Control Rate for Follow-up Period of 5 Years. — 99 percentage of subjects
Phase 2 N=36 Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
Breast Cancer · Stage II Breast Cancer · Stage III Breast Cancer
Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants
N/A N=13 Circumferential Periareolar Mastopexy Using SERI Surgical Scaffold
Mastopexy
Primary: Number of Participants With Areolar Dilation of up to 6mm at 12 Months — 13 Participants
N/A N=97 Study of Prone Accelerated Breast And Nodal IMRT
Lymphedema
Primary: Number of Participants With Acute Toxicity > Grade 2 (Skin Toxicity Grade 3 or Above) Occurring Within 60 Days After First Day of Treatment — 4 Participants